Yuhan Corporation (KRX:000100) disclosed a ₩131.1bn active pharmaceutical ingredient order on September 1, worth $95.4m, running to May 2028 with the buyer sealed until the day it ends.
Yuhan Corporation (000100) said in a filing Tuesday that it signed a contract to supply active pharmaceutical ingredient (API) to a buyer it identifies only as "a global pharmaceutical company," worth KRW 131.07bn (~$95.4m at the day's exchange rate).
| Period | 000100 | KOSPI | Difference |
|---|---|---|---|
| 1 week | -4.1% | -1.5% | -2.6% |
| 1 month | +8.8% | +5.2% | +3.7% |
| 3 months | +1.6% | -22.6% | +24.2% |
| 6 months | -11.9% | +31.3% | -43.2% |
| Year to date | -27.6% | +58.7% | -86.3% |
| 1 year | -31.1% | +108.9% | -140.0% |
Closed at 26% of the way from its 52-week low (₩66,400) to its 52-week high (₩125,000).
Yuhan signed a product-supply contract to deliver active pharmaceutical ingredient (API) to a counterparty it identifies only as "a global pharmaceutical company." The contract is worth ₩131.07bn (USD 95.42m at the September 1, 2026 rate of ₩1,373.60/$1) — about 6% of Yuhan's FY2025 consolidated revenue of ₩2.19tn, a ratio the filing states directly. It runs from September 1, 2026 to May 31, 2028 (roughly 21 months), carries no advance or down payment, and the delivery region is listed as undetermined. The filing does not say what drug the API supports or disclose which company is buying it.
Yuhan is one of Korea's oldest pharmaceutical companies, selling everyday medicines and consumer health products in its home market. Its profile changed when it out-licensed the lung-cancer drug lazertinib to Johnson & Johnson, which now sells it in the United States paired with its own antibody. That deal gives Yuhan milestone payments and royalties tied directly to American prescriptions. It shows how a conventional Korean drugmaker can end up with exposure to a US oncology launch.
| Sector | Biopharma | Employees | |
| Market | KOSPI | Founded | |
| Korean name | 유한양행 | Head office |
| Symbol | Last Price |
|---|---|
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |